Health Care & Life Sciences » Biotechnology | ImmunoCellular Therapeutics Ltd.

ImmunoCellular Therapeutics Ltd. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
27,646.40
23,222.30
22,604.50
11,437.10
6,629.90
Inventories
-
-
1,158.60
1,186.20
-
Other Current Assets
763.30
1,219.90
797.40
791.50
378.80
Total Current Assets
28,409.70
24,442.20
24,560.50
13,414.80
7,008.70
Net Property, Plant & Equipment
66.40
47.40
180.90
109.80
0.60
Other Assets
464.60
689.00
5,340.90
3,365.40
-
Total Assets
28,940.70
25,178.60
30,082.40
16,890.00
7,009.20
Accounts Payable
861.00
-
-
-
1,774.60
Other Current Liabilities
541.20
1,289.20
2,269.40
3,238.90
586.10
Total Current Liabilities
1,402.30
1,289.20
2,269.40
3,238.90
2,360.80
Other Liabilities
1,064.80
597.70
6,092.70
7,519.30
-
Total Liabilities
2,467.10
1,886.90
8,362.10
10,758.20
2,360.80
Common Equity (Total)
26,473.60
23,291.60
21,720.30
6,131.70
4,648.50
Total Shareholders' Equity
26,473.60
23,291.60
21,720.30
6,131.70
4,648.50
Total Equity
26,473.60
23,291.60
21,720.30
6,131.70
4,648.50
Liabilities & Shareholders' Equity
28,940.70
25,178.60
30,082.40
16,890.00
7,009.20

About ImmunoCellular Therapeutics

View Profile
Address
30721 Russell Ranch Road
Westlake Village California 91362
United States
Employees -
Website http://www.imuc.com
Updated 07/08/2019
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.